Belgium will not reimburse Mounjaro for obesity
The Belgian government is limiting reimbursement of tirzepatide to certain patients with type 2 diabetes.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
Belgium will not reimburse Mounjaro when it is used to treat obesity. Manufacturer Eli Lilly criticises the decision and warns of unequal access to treatment.
According to Belgian medicines information, Mounjaro contains tirzepatide and is reimbursable in Belgium under certain conditions for some patients with type 2 diabetes. Patients using it to treat obesity must pay for the treatment themselves. The lowest dosage costs approximately €179 a month, according to Belgian reports.
Health Minister Frank Vandenbroucke defends the decision, referring to the costs and the limits of medication as a standalone solution for obesity. His cabinet says that support from dietitians, psychologists and physiotherapists, among others, is also needed.
Eli Lilly, the American manufacturer of Mounjaro, regrets the decision. The company says that patients who cannot afford the medicine themselves will consequently have no access to it. That response comes from an interested party and is not independent research into the policy’s consequences.
Earlier this week, the Belgian health authorities warned against improper and unregistered use of GLP-1 medicines and similar drugs for weight loss. The Belgian medicines authority emphasises that the authorised indications differ from product to product and that the medicines must be used as prescribed.
The debate therefore concerns more than one medicine. Belgium must determine which treatments are paid for through compulsory health insurance, for which patient groups and under what conditions. Medical effectiveness, budgetary capacity and equal access all play a role at the same time.
For Dutch readers, the Belgian decision is particularly relevant as an example of a European reimbursement debate that is also taking place in the Netherlands. The decision says nothing about the reimbursement or medical suitability of Mounjaro in the Netherlands. Readers should therefore not draw any conclusions about their own treatment from the Belgian rules.
Also show where in Europe and in the world
One story, several perspectives
What is established
- Belgium does not reimburse Mounjaro for the obesity indication.
- Subject to certain conditions, reimbursement is available for some patients with type 2 diabetes.
- The Belgian medicines authority warned against improper and off-label use of GLP-1 medicines.
Left
Arguments A left-wing perspective emphasises that obesity is a chronic condition and that access to effective treatment should not depend on income. From this viewpoint, limited reimbursement could increase existing health inequalities.
Values Equal access, public healthcare and solidarity.
Consequences Wider reimbursement could help patients, but would increase pressure on healthcare budgets and require clear medical criteria.
Centre
Arguments Reimbursement should be linked to demonstrable medical added value, support and budgetary feasibility. A phased system with evaluation could prevent the insurance system from facing unmanageable costs.
Values Carefulness, efficiency, affordability and medical substantiation.
Consequences A limited initial group would keep costs manageable, but would temporarily leave some patients without reimbursement.
Right
Arguments The government should be cautious about collectively paying for expensive medicines when lifestyle support and targeted care could be given priority. Individuals and insurers should retain room to make additional choices themselves.
Values Personal responsibility, affordability and limited government intervention.
Consequences Limited public reimbursement could protect the budget, but would widen the gap between people who can and cannot afford the medicine themselves.
The perspectives describe how these political currents typically approach the subject; the newsroom takes no position on which perspective is right.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
Reimbursement for diabetes and the absence of reimbursement for obesity have been confirmed by Belgian sources. The text carefully attributes interests and possible consequences and does not provide medical advice.
- confirmed Mounjaro is not reimbursed in Belgium for obesity, but is reimbursed under certain conditions for some diabetes patients. — Confirmed by The Brussels Times and Belgian medicines information. source
- confirmed The lowest dosage costs approximately €179 a month. — Mentioned in reporting on the Belgian decision. source
- confirmed The Belgian medicines authority warned against improper and off-label use. — Official warning from FAGG. source
Editor's note
The Belgian reimbursement restriction and the responses to it have been confirmed. The exact future costs for health insurance and the consequences for patients have not yet been independently established.Sources
- Belgian Health Minister halts reimbursement for obesity drug Mounjaro — The Brussels Times
- GLP-1 analogues and GIP/GLP-1 dual analogues: risks associated with misuse and off-label use for weight loss — Belgisch Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten
- Lilly déplore le non-remboursement de son traitement contre l'obésité Mounjaro en Belgique — Pharma-Sphere
More on this in Dutch media
- AD — „belgië mounjaro”
- de Volkskrant — „belgië mounjaro”
- RTL Nieuws — „belgië mounjaro”